Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
暂无分享,去创建一个
P. van Paassen | V. Tesar | C. Savage | R. Luqmani | D. Jayne | J. Tervaert | K. Westman | M. Segelmark | T. Hauser | M. Walsh | M. Morgan | C. Peh | R. B. Jones | D. Walsh | R. Jones
[1] D A Bloch,et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. , 2010, Arthritis and rheumatism.
[2] D. Altman,et al. Analysing controlled trials with baseline and follow up measurements , 2001, BMJ : British Medical Journal.
[3] A. Loft,et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. , 2008, The Journal of rheumatology.
[4] Anastasia E. Raczek,et al. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. , 1992, Medical care.
[5] C. Pusey,et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] Stanley B. Cohen,et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.
[7] D. Furst,et al. Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials , 2010 .
[8] P. Emery,et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.
[9] B. Haynes,et al. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. , 1979, The New England journal of medicine.
[10] M. Falagas,et al. Infectious complications of monoclonal antibodies used in cancer therapy , 2007, Cancer.
[11] C. Gordon,et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.
[12] R. Porter. Nomenclature of Systemic Vasculitides: Proposal of an International Consensus Conference , 1995 .
[13] A. Fauci,et al. Suppression of human B lymphocyte function by cyclophosphamide. , 1982, Journal of immunology.
[14] C. Kallenberg,et al. Differential B- and T-cell activation in Wegener's granulomatosis. , 1999, The Journal of allergy and clinical immunology.
[15] A. Feller,et al. B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesions , 2005, Annals of the rheumatic diseases.
[16] V. Tesar,et al. Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis , 2009, Annals of Internal Medicine.
[17] C. Kallenberg,et al. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. , 2006, Rheumatology.
[18] Kenneth G. C. Smith,et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. , 2009, Arthritis and rheumatism.
[19] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[20] J. Stone,et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. , 2005, Arthritis and rheumatism.
[21] D. Revicki,et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. , 2008, The Journal of rheumatology.
[22] David Steven Scott,et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.
[23] R. Falk,et al. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. , 2006, Journal of the American Society of Nephrology : JASN.
[24] Jianwen Cai,et al. Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic AntibodyAssociated Small-Vessel Vasculitis , 2005, Annals of Internal Medicine.
[25] S. Amadori,et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. , 2006, Rheumatology.
[26] A. Müller,et al. Is PR3‐ANCA Formation Initiated in Wegener's Granulomatosis Lesions? Granulomas as Potential Lymphoid Tissue Maintaining Autoantibody Production , 2005, Annals of the New York Academy of Sciences.
[27] M. Krumbholz,et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. , 2005, Journal of autoimmunity.
[28] Kenneth G. C. Smith,et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. , 2006, Arthritis and rheumatism.
[29] Sabina A Antoniu. Rituximab for refractory Wegener’s granulomatosis , 2006, Expert opinion on investigational drugs.
[30] H. Raspe,et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force , 2007, Annals of the rheumatic diseases.
[31] D. Jayne. Role of rituximab therapy in glomerulonephritis. , 2010, Journal of the American Society of Nephrology : JASN.
[32] H. Raspe,et al. EULAR recommendations for the management of primary small and medium vessel vasculitis , 2008, Annals of the Rheumatic Diseases.
[33] K. Chakravarty,et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. , 2007, Rheumatology.
[34] V. Tesar,et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. , 2003, The New England journal of medicine.
[35] P. Emery,et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.
[36] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] D. Abramowicz,et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. , 2007, Journal of the American Society of Nephrology : JASN.
[38] A. Steinberg,et al. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. , 1991, Arthritis and rheumatism.
[39] D. Jayne,et al. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. , 2007, Kidney international.
[40] C. Gordon,et al. Malignancy is increased in ANCA-associated vasculitis. , 2004, Rheumatology.
[41] L. Guillevin,et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. , 2008, Arthritis and rheumatism.
[42] R. Panush. Rituximab versus cyclophosphamide for ANCA-associated vasculitis , 2011 .
[43] B. Rovin,et al. Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. , 2009, Clinical journal of the American Society of Nephrology : CJASN.